3-(diethylamino)propyl 3-((5-(4-chlorophenyl)-2-oxo-2H-1,3,4-thiadiazin-3(6H)-yl)methyl)phenylcarbamate

ID: ALA3402763

Chembl Id: CHEMBL3402763

PubChem CID: 16734139

Max Phase: Preclinical

Molecular Formula: C24H29ClN4O3S

Molecular Weight: 489.04

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCN(CC)CCCOC(=O)Nc1cccc(CN2N=C(c3ccc(Cl)cc3)CSC2=O)c1

Standard InChI:  InChI=1S/C24H29ClN4O3S/c1-3-28(4-2)13-6-14-32-23(30)26-21-8-5-7-18(15-21)16-29-24(31)33-17-22(27-29)19-9-11-20(25)12-10-19/h5,7-12,15H,3-4,6,13-14,16-17H2,1-2H3,(H,26,30)

Standard InChI Key:  XSINRHAIBWWSLP-UHFFFAOYSA-N

Associated Targets(Human)

MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE3A Tclin Phosphodiesterase 3 (1749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE4A Tclin Phosphodiesterase 4 (3344 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 489.04Molecular Weight (Monoisotopic): 488.1649AlogP: 5.69#Rotatable Bonds: 10
Polar Surface Area: 74.24Molecular Species: BASEHBA: 6HBD: 1
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.01CX Basic pKa: 10.00CX LogP: 4.92CX LogD: 2.37
Aromatic Rings: 2Heavy Atoms: 33QED Weighted: 0.43Np Likeness Score: -1.67

References

1. Dorsch D, Schadt O, Stieber F, Meyring M, Grädler U, Bladt F, Friese-Hamim M, Knühl C, Pehl U, Blaukat A..  (2015)  Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.,  25  (7): [PMID:25736998] [10.1016/j.bmcl.2015.02.002]

Source